5-MeO-DMT (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "5-MeO-DMT" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
3,887th place
3,961st place
doi.org
dx.doi.org
- Araújo AM, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M (agosto de 2015). «The hallucinogenic world of tryptamines: an updated review». Archives of Toxicology. 89: 1151–73. PMID 25877327. doi:10.1007/s00204-015-1513-x
- Ott J (julho–setembro de 2001). «Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine». Journal of Psychoactive Drugs. 33: 273–81. PMID 11718320. doi:10.1080/02791072.2001.10400574
- Shen HW, Jiang XL, Winter JC, Yu AM (outubro de 2010). «Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions». Current Drug Metabolism. 11: 659–66. PMC 3028383
. PMID 20942780. doi:10.2174/138920010794233495 - Davis, Alan K.; So, Sara; Lancelotta, Rafael; Barsuglia, Joseph P.; Griffiths, Roland R. (março de 2019). «5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety». The American Journal of Drug and Alcohol Abuse. 45: 161–169. PMC 6430661. PMID 30822141. doi:10.1080/00952990.2018.1545024
- Davis, Alan K; Barsuglia, Joseph P; Lancelotta, Rafael; Grant, Robert M; Renn, Elise (30 de abril de 2018). «The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption». Journal of Psychopharmacology. 32: 779–792. PMC 6248886. PMID 29708042. doi:10.1177/0269881118769063
- Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA (dezembro de 2006). «The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats». Psychopharmacology. 189: 319–29. PMID 17013638. doi:10.1007/s00213-006-0566-1
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (março de 2007). «The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain». European Journal of Pharmacology. 559: 132–7. PMID 17223101. doi:10.1016/j.ejphar.2006.11.075
- Uthaug MV, Lancelotta R, van Oorsouw K, Kuypers KP, Mason N, Rak J, Šuláková A, Jurok R, Maryška M, Kuchař M, Páleníček T, Riba J, Ramaekers JG (setembro de 2019). «A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms». Psychopharmacology. 236: 2653–2666. PMC 6695371. PMID 30982127. doi:10.1007/s00213-019-05236-w
erowid.org
- «5-MeO-DMT Timeline». Erowid
nih.gov
ncbi.nlm.nih.gov
- Araújo AM, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M (agosto de 2015). «The hallucinogenic world of tryptamines: an updated review». Archives of Toxicology. 89: 1151–73. PMID 25877327. doi:10.1007/s00204-015-1513-x
- Ott J (julho–setembro de 2001). «Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine». Journal of Psychoactive Drugs. 33: 273–81. PMID 11718320. doi:10.1080/02791072.2001.10400574
- Shen HW, Jiang XL, Winter JC, Yu AM (outubro de 2010). «Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions». Current Drug Metabolism. 11: 659–66. PMC 3028383. PMID 20942780. doi:10.2174/138920010794233495
- Davis, Alan K.; So, Sara; Lancelotta, Rafael; Barsuglia, Joseph P.; Griffiths, Roland R. (março de 2019). «5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety». The American Journal of Drug and Alcohol Abuse. 45: 161–169. PMC 6430661. PMID 30822141. doi:10.1080/00952990.2018.1545024
- Davis, Alan K; Barsuglia, Joseph P; Lancelotta, Rafael; Grant, Robert M; Renn, Elise (30 de abril de 2018). «The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption». Journal of Psychopharmacology. 32: 779–792. PMC 6248886. PMID 29708042. doi:10.1177/0269881118769063
- Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA (dezembro de 2006). «The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats». Psychopharmacology. 189: 319–29. PMID 17013638. doi:10.1007/s00213-006-0566-1
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (março de 2007). «The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain». European Journal of Pharmacology. 559: 132–7. PMID 17223101. doi:10.1016/j.ejphar.2006.11.075
- Uthaug MV, Lancelotta R, van Oorsouw K, Kuypers KP, Mason N, Rak J, Šuláková A, Jurok R, Maryška M, Kuchař M, Páleníček T, Riba J, Ramaekers JG (setembro de 2019). «A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms». Psychopharmacology. 236: 2653–2666. PMC 6695371. PMID 30982127. doi:10.1007/s00213-019-05236-w